Loss of protein kinase Cβ function protects mice against diet-induced obesity and development of hepatic steatosis and insulin resistance

Authors

  • Wei Huang,

    1. Departments of Molecular and Cellular Biochemistry, Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH
    Search for more papers by this author
  • Rishipal Bansode,

    1. Departments of Molecular and Cellular Biochemistry, Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH
    Search for more papers by this author
  • Madhu Mehta,

    1. Department of Internal Medicine, Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH
    Search for more papers by this author
  • Kamal D. Mehta

    Corresponding author
    1. Departments of Molecular and Cellular Biochemistry, Dorothy M. Davis Heart & Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH
    • Department of Molecular and Cellular Biochemistry, The Ohio State University College of Medicine, 464 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210
    Search for more papers by this author
    • fax: 614-292-4118


  • Potential conflict of interest: Nothing to report.

Abstract

Obesity is an energy balance disorder in which intake is greater than expenditure, with most excess calories stored as triglyceride (TG). We previously reported that mice lacking the β-isoform of protein kinase C (PKCβ), a diacylglycerol- and phospholipid-dependent kinase, exhibit marked reduction in the whole body TG content, including white adipose tissue (WAT) mass. To investigate the role of this signaling kinase in metabolic adaptations to severe dietary stress, we studied the impact of a high-fat diet (HFD) on PKCβ expression and the effect of PKCβ deficiency on profound weight gain. We report herein that HFD selectively increased PKCβ expression in obesity-prone C57BL/6J mice, specifically in WAT; the expression levels were little or unchanged in the liver, muscle, kidney, and heart. Basal PKCβ expression was also found to be elevated in WAT of obese ob/ob mice. Remarkably, mice lacking PKCβ were resistant to HFD-induced obesity, showing significantly reduced WAT and slightly higher core body temperatures. Unlike lean lipodystrophic mouse models, these mice did not have fatty livers, nor did they exhibit insulin resistance. Moreover, PKCβ−/− mice exhibited changes in lipid metabolism gene expression, and such alterations were accompanied by significant changes in serum adipokines. These observations suggest that PKCβdeficiency induced a unique metabolic state congruous with obesity resistance, thus raising the possibility that dysregulation of PKCβ expression could contribute to dietary fat–induced obesity and related disorders. (HEPATOLOGY 2009.)

There is a worldwide epidemic of obesity and type 2 diabetes1, 2 that parallels the “westernization” of diet, which is characterized by high-fat and higher caloric intake.3 Because 80% of patients with type 2 diabetes are obese, and obesity is associated with insulin resistance,4 attention has been focused on the identification of molecular targets for fat storage and the characterization of links between obesity and insulin resistance. One mechanism that has been proposed as a cause of obesity-induced insulin resistance is an elevation in intracellular fatty acid metabolites, such as fatty acyl coenzyme A and diacylglycerol. This results in tissue-specific activation of specific isoforms of protein kinase C (PKC) that lead to the impairment of insulin signaling and activity.5–10 Alterations in the expression levels and/or activities of several lipid-dependent PKC isoforms have been associated with insulin resistance in type 2 diabetic patients, animal models of diabetes, and cellular models.11, 12 In mammals, the PKC family is quite heterogeneous, comprising 11 isoforms divided into three major subsets: conventional (α, βI, βII, and γ), novel (δ, ϵ, η, and θ), and atypical (λ and ζ) isoforms.13, 14 Each isoform is encoded by a separate gene, with the exception of the β1 and βII isoforms, which are splice variants. In fact, among the ubiquitously expressed family of serine/threonine kinases, PKCβ is the only subtype that is expressed through two splice variants.15 The biological significance of this heterogeneity has not been clarified, but it appears that the members of this enzyme family are activated in specific intracellular compartments in different ways, depending on the distribution of membrane lipid metabolites, and play distinct roles in the control of major cellular functions.14, 16

Previous studies have firmly established that diabetic conditions activate diacylglycerol–PKC signaling.10, 12 Diabetes-induced PKC activity does not appear to be isoform-generalized, but is rather restricted to a few “diabetic-related” isoforms in a tissue-specific manner. PKCβ is one of those isoforms and has been most directly linked to important aspects of hyperglycemia in vivo and in vitro. Insulin is known to stimulate PKCβ activity in order to promote glucose disposal.17 PKCβ is also shown to inhibit several components of the insulin signaling cascade and the downstream metabolic enzymes, including glycogen synthase.18 There is also evidence that PKCβ may act upstream of other serine and threonine kinases. For example, PKCβ activation can enhance the ability of kinases,such as Jun amino-terminal kinase and inhibitor of kB kinase to phosphorylate insulin receptor substrate-1 at Ser307, a key regulatory site located near the domain that interacts with the insulin receptor.19, 20 On the other hand, PKCβ is also known to act upstream of mitogen/extracellular-regulated kinase to promote Ser612 phosphorylation of insulin receptor substrate-1, which modulates phosphatidylinositol-3-kinase activation.21–23 Moreover, variations in the promoter region of the human PKCβ gene are associated with alterations in insulin sensitivity.24, 25 Finally, in vivo inhibition of PKCβ reverses diabetes-induced vascular dysfunction, thereby identifying a definitive role for PKCβ in the pathogenesis of diabetic complications.26

Metabolic pathways leading to adiposity from consumption of dietary fat are incompletely understood. Due to a link between lipids and PKC activation, dietary fat has also been examined as a modulator of PKC activity in several tissue types from a range of animal species.27–30 Providing various types and levels of fat in the diet of animals has been shown to produce alterations in PKCβ translocation and activation in a variety of tissues. For example, increased translocation of cardiac PKCβII has been shown to accompany mild cardiac hypertrophy in rats that were fed a diet rich in saturated fat.31 The extent to which PKCβ exerts control on visceral adiposity, triglyceride (TG) storage, and insulin sensitivity is not clear. The importance of PKCβ in lipid metabolism was recently unraveled in our previous study of PKCβ–deficient (PKCβ−/−) mice, in which we showed that loss of PKCβ function is associated with a marked reduction in adipose mass, significantly reduced TG stores in insulin-sensitive tissues, increased metabolic rate and oxygen consumption, and reduced body weight despite increased food intake.32 The marked decrease of TG levels in PKCβ−/− mice suggested alterations in lipid uptake or metabolism of PKCβ mice. To understand further the physiological role of PKCβ and its potential to regulate systemic TG homeostasis, we evaluated whether PKCβ expression and its distribution is influenced by high-fat feeding and also assessed the impact of PKCβ deficiency on obesity and its accompanying metabolic disorders under conditions of severe dietary stress. We now report tissue- and isoform-specific up-regulation of adipose PKCβ expression in two obesity mouse models. Mice with a targeted disruption of PKCβ are resistant to dietary fat–induced obesity and the development of insulin resistance. Moreover, PKCβ−/− mice exhibited changes in lipid metabolism gene expression, and such alterations were accompanied by significant alterations in serum adipokines. Our data raise the possibility that dysregulation of PKCβ expression can be associated with susceptibility to high-fat diet (HFD)-induced obesity.

Abbreviations

BAT, brown adipose tissue; HFD, high-fat diet; mRNA, messenger RNA; PKCβ, protein kinase Cβ; PKCβ−/−, PKCβ-deficient; SREBP, sterol response element-binding protein; TG, triglycerides; UCP, uncoupling protein; WAT, white adipose tissue; WT, wild-type.

Materials and Methods

Animals and Diet.

Production of PKCβ−/− mice in C57BL/6J background and genotypic determination were performed as described.32 Six-week-old PKCβ−/− and WT controls were fed ad libitum for 12 weeks continuously either a HFD (D12492; Research Diets, New Brunswick, NJ) in which 60% of the total calories were derived from fat (soybean oil and lard) or a standard diet containing 15% kcal from fat (7912 rodent chow; Harland Tekland, WI). PKCβ−/− and WT mice were housed under controlled temperature (23°C) and lighting (12 hours light/dark) with free access to water. C57BL6/J WT mice were obtained from Jackson Laboratory (Bar Harbor, ME). All procedures on mice followed guidelines established by the Ohio State University College of Medicine Animal Care Committee. Unless indicated, all experiments were performed on male animals starved for approximately 16 hours.

Histological Analysis of Tissues.

Liver, white adipose tissue (WAT), and brown adipose tissue (BAT) were isolated from WT and PKCβ−/− mice and fixed in 4% paraformaldehyde in phosphate-buffered saline and processed for paraffin sections and stained with hematoxylin-eosin. Cross-sectional areas of adipocytes were measured using Image J software by counting at least 300 individual cells from random fields in histological sections. Nonperfused livers and WAT were digested in chloroform-methanol to determine hepatic TG levels. TG concentrations were determined with a TG assay kit according to the manufacturer's instructions. Livers were also snap-frozen in Tissue-Tek OCT. Cryostat sections of livers were fixed with 4% paraformaldehyde–phosphate buffered saline for 1 hour and cryoprotected with 20% sucrose prior to staining with 4% oil red O for 2 hours.

Glucose Tolerance Test and Insulin Tolerance Test.

A glucose tolerance test and insulin tolerance test were performed on fasted (16 hours) mice. Mice were weighed and then injected intraperitoneally with either glucose (1.5 mg/kg body weight) or insulin (Humulin; Lilly; 0.8 U/kg body weight). Blood samples were via tail bleeds at baseline and at indicated time intervals after glucose or insulin injection and analyzed for glucose and insulin levels. Plasma insulin levels were measured via ELISA using a kit from LINCO Research (St. Charles, MO).

Blood, Serum, and Tissue Analyses.

Plasma and tissue TG or cholesterol concentrations were measured by colorimetric kit assays (Roche Diagnostics). Serum glucose was measured by colorimetric method. Immunoreactive insulin was measured using a sensitive insulin RIA kit from Linco Inc. Serum leptin and adiponectin levels were measured via enzyme-linked immunosorbent assay kits (Linco, Inc.) according to the manufacturer's protocol. Nonesterified fatty acids were measured using NEFA-HR(2) from Wako. Serum TG was measured using the Serum TG determination kit from Sigma-Aldrich. Tissue TG contents were determined with a TG 320A kit (Sigma) as described. For comparative analysis of tissue lipids, lipids were extracted from tissues and separated on ALSILG Silica Gel TLC plates (Whatman) using hexane/ethyl ether/acetic acid (83:16:1).

Tissue Extraction.

WAT was fractionated as described.33 Epididymal fat pads were homogenized and centrifuged at 1,000g, and supernatants were collected and subjected to another centrifugation at 100,000g for 1 hour at 4°C. The supernatants were collected as soluble fractions and referred to as the cytosol fraction. The pellets were dissolved in with ice-cold buffer in a volume equal to that of soluble fractions and were termed the membrane fraction.

Western Blotting.

Tissue samples were snap-frozen, pulverized, and dispersed in lysis buffer.32, 34 Samples were loaded onto 8% acrylamide gels and blotted. Anti-PKCβ and anti-SREBP-1 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Immunoreactive proteins were visualized via enhanced chemiluminescence (ECL plus; Amersham, Arlington Heights, IL) and quantified via densitometry using Molecular Analyst software (Bio-Rad).

Gene Expression Analysis.

Gene expression analysis was performed as described.32, 34 To ensure the validity of the SYBR green–based messenger RNA (mRNA) quantifications, most of the mRNAs were quantified using32P-labeled 2′-deoxycytidine 5′-triphosphate. This alternative method and the SYBR green method yielded similar results. All data are expressed as the fold induction relative to each control value.

Statistical Analysis.

Statistical comparison of the results was performed using an unpaired Student t test.

Results

Dietary Fat Induces PKCβ Expression in an Isoform- and Tissue-Specific Manner.

It is well demonstrated that C57BL/6J mice develop severe obesity accompanied by hyperglycemia when fed an HFD.35 Therefore, these mice are among the several strains of mice classified as sensitive to diet-induced obesity. To address the relationship between dietary fat and PKCβ expression, we examined the effects of an HFD on expression levels of PKC isoforms in different tissues. After 12 weeks of feeding, PKCβ mRNA levels were significantly increased selectively in WAT (four-fold; P < 0.001) and BAT (three-fold; P < 0.05) compared with those on a low-fat diet; expression levels were little or unchanged in the liver, muscle, kidney, brain, or heart (Fig. 1A,B). The expression levels of other PKC isoforms were not altered significantly, except for slight increases in adipose PKCα and PKCθ expression on an HFD. To further verify that PKCβ was overexpressed upon HFD feeding, PKCβ protein levels were examined in WAT. Indeed, expression levels of PKCβ protein were increased in the WAT of HFD-fed mice (Fig. 1D).

Figure 1.

Induction of adipose PKCβ expression by HFD in C57BL/6J mice and ob/ob mice fed a chow diet exhibited elevated adipose PKCβ expression. (A) Relative mRNA levels of different PKC isoforms in WAT of starved (16 hours) C57BL/6J WT mice fed either a normal chow or an HFD for 12 weeks. (B) Relative PKCβ mRNA levels in different tissues of HFD-fed WT mice. (C) Expression levels of different PKC isoforms and mRNA in the WAT of starved (16 hours) ob/ob mice fed a chow diet and control lean animals on the same diet. Total RNA was isolated and used for assessment of levels of different PKC isoforms. β-Actin was used as a control in all experiments. (D) Abundance of PKCβ was determined via western blot analysis using anti-PKCβ serum (Santa Cruz Biotechnology, Santa Cruz, CA). Densitometric analysis of the PKCβ band is shown. Results are expressed as the mean ± standard deviation. *P < 0.05; **P < 0.01.

Elevated Basal Adipose PKCβ Expression in ob/ob Mice.

The obese ob/ob mouse is an excellent model of obesity induced by insulin resistance, overeating, and overweight.36 To evaluate the regulation of PKCβ by obesity and hyperinsulinemia in vivo, we measured PKCβ expression in different tissues of 18-week-old C57BL/6J ob/ob mice and lean counterpart C57BL/6J WT mice. As shown in Fig. 1C, basal PKCβ mRNA expression was significantly increased in the WAT of ob/ob mice by 531 ± 56% compared with C57Bl/6J WT mice (P < 0.001), whereas no significant differences were observed in other tissues (Fig. 1C). Moreover, expression levels of other PKC isoforms were little or unchanged in ob/ob WAT.

PKCβ Deficiency Ameliorated Diet-Induced Obesity.

Diet-induced changes in adipose PKCβ expression raised the possibility that expression of this kinase might be regulated physiologically to enhance dietary fat storage. To address the relation between PKCβ expression and susceptibility to obesity, we compared responses of WT and PKCβ−/− mice under conditions of severe dietary stress. Both PKCβ−/− and WT mice were fed an HFD for 12 weeks, beginning at 6 weeks of age. Body weights and food intake were monitored weekly, and at the end we examined weights of WAT, BAT, and various metabolic parameters. A significant increase in WT mice body weights were evident after only 3 weeks on an HFD, and this trend continued throughout the dietary protocol (Fig. 2A). However, PKCβ−/− mice fed an HFD gained less weight and exhibited an obese-resistant phenotype (Fig. 2A,B). Whereas body weights of PKCβ−/− mice were less than WT mice, PKCβ−/− mice appeared to be mildly hyperphagic and consistently consumed a greater caloric load (Fig. 2A). When energy intake was calculated relative to increased body weight (feed efficiency) over the 12-week period, PKCβ−/− mice consistently exhibited a lower feed efficiency (that is, they required more energy intake relative to body weight gained) compared with WT mice (1.27 ± 0.12 versus 2.1 ± 0.29 body weight gain/g HFD/week, respectively; P < 0.001) (Fig. 2A). It is thus clear that the decreased body weight was not a result of decreased food intake.

Figure 2.

PKCβ−/− mice are resistant to HFD-induced obesity. (A) Body weights, food intakes, and feed efficiencies in WT and PKCβ−/− mice fed an HFD. At 6 weeks of age, mice were fed an HFD for a period of 12 weeks and were weighed weekly. Values represent the means ± standard deviation of WT and PKCβ−/− mice (n = 6). (B) Gross representative images of WT and PKCβ−/− mice and the abdominal view of the fat pads under the skin following 12 weeks of an HFD. (C-E) Representative pictures and weights of livers, WAT, and BAT for the same group (n = 6). Values represent the mean ± standard deviation of WT and PKCβ−/− mice (n = 6). *P < 0.05; **P < 0.001.

To determine if changes in weights were associated with differences in adiposity, we compared changes in adipose fat pads in WT and PKCβ−/− mice on an HFD. The weights of WAT (2.42 ± 0.27 g [WT] versus 0.85 ± 0.12 g [PKCβ−/−]; P < 0.001) (Fig. 2C) and BAT (0.32 ± 0.07 g [WT] versus 0.19 ± 0.001 g [PKCβ−/−]; P < 0.05) (Fig. 2D) in PKCβ−/− mice were dramatically reduced when compared with WT mice, indicating that these mice are strongly protected from diet-induced obesity. The weights of PKCβ−/− livers were also lower than those of WT (0.9 ± 0.1 g versus 1.48 ± 0.17 g, respectively; P < 0.001) (Fig. 2E), whereas various other tissues were of similar weight. There was a slight change in the liver color of PKCβ−/− mice; however, no obvious morphological differences were observed in other tissues. Histological examination of these livers revealed increased numbers and sizes of intracellular vacuoles—an indication of fatty liver—in WT mice compared with PKCβ−/− mice (Fig. 3A). Oil red O staining of liver sections verified deposition of increasing quantities of lipids in WT liver (Fig. 3A). Histological analysis of WAT revealed that adipocytes from PKCβ−/− mice were significantly smaller than those from WT mice (Fig. 3A). The thickness of adipose tissue beneath the dermis in PKCβ−/− mice was also clearly reduced compared with WT mice (Fig. 3B). As expected, based on histological analysis, chemical analysis of livers and muscles revealed elevated TG contents in WT mice compared with PKCβ−/− mice, with a greater than seven-fold and three-fold difference, respectively (Fig. 3C-E). Elevated hepatic TG in WT mice was reflected by a slight color change in the livers of these animals, even though their cholesterol levels remained same (Fig. 3F).

Figure 3.

Histological and biochemical changes in liver, adipose, muscle, and skin from WT and PKCβ−/− mice. (A, B) Histological sections of livers (magnification ×20), WAT (magnification ×20), BAT (magnification ×20), and skin (magnification ×4) were prepared and stained with hematoxylin-eosin or oil red O. Bar = 50 μm for liver, WAT, and BAT. Bar = 100 μm for skin. Results are representative of n = 6 in each group. Each value represents the mean ± standard deviation. (C-D) Relative amounts of lipid contents in the liver and muscle of WT and PKCβ−/− mice following HFD feeding for 12 weeks (fasted 16 hours). Each value represents the mean ± standard deviation (n = 5-10 mice per group). (E) Thin layer chromatography of total lipid extracts from livers (L) and muscles (M) of WT and PKCβ−/− mice is also shown. Each lane represents lipids from the liver and muscle of three mice. *P < 0.001. (F) Liver cholesterol contents of WT and PKCβ−/− mice. Each value represents the mean ± standard deviation.

Consistent with adipose tissue mass, PKCβ−/− mice fed an HFD for 12 weeks exhibited significantly lower levels of serum leptin (29.1 ± 2.5 WT versus 0.9 ± 0.3 mEq/l PKCβ−/−; P < 0.001) (Fig. 4A). In contrast, plasma adiponectin levels were slightly elevated, but never reached a significant level, in PKCβ−/− mice compared with WT mice (38.9 ± 6.4 ng/mL versus 32.9 ± 4.3, respectively; P value not significant) (Fig. 4A). Consequently, food intake, which is regulated by plasma levels of leptin, was more than 20% higher in PKCβ−/− mice than in WT mice (Fig. 3A). Leptin values observed in PKCβ−/− mice were significantly lower than what would be expected based on reduction in WAT. Decreased leptin values in PKCβ−/− mice were more than could be explained by reduction in body weight alone. In view of these results, leptin and adiponectin mRNA levels were assessed in WAT and BAT. Leptin mRNA was 10-fold lower in PKCβ−/− mice on an HFD (Fig. 4B), suggesting that decreased expression of this hormone in PKCβ−/− mice further contributed to lower circulating levels. Surprisingly, adiponectin mRNA is not significantly different between WT and PKCβ−/− mice, despite a three-fold decrease of WAT in PKCβ−/− mice.

Figure 4.

Comparison of metabolic profiles of WT and PKCβ−/− mice fed an HFD for 12 weeks. (A) Serum leptin and adiponectin levels. (B) Relative leptin and adiponectin mRNA levels in the WAT of WT and PKCβ−/− mice fed either a chow diet or an HFD. (C) Plasma TG, cholesterol, and free fatty acid levels. (D) Comparison of body temperatures. Each value represents the mean ± standard deviation (n = 5-10 mice per group). *P < 0.05; **P < 0.001. (E) Comparison of hepatic mature SREBP-1 levels in WT (given an arbitrary value of 1) and PKCβ−/− mice as revealed via western blotting using anti-SREBP-1 (K-10) from Santa Cruz Biotechnology. A representative autoradiograph is shown in the inset. Autoradiographs were quantitated densitometrically and the results are normalized to the levels of β-actin. Values shown are averages of two different experiments.

Explanations for the surprising phenotype include deficiency in intestinal food absorption and/or abnormalities in lipid clearance, metabolism, or storage. To distinguish between these possibilities, we examined circulating TG, cholesterol, and free fatty acid levels. We hypothesized that lipid levels would be increased if lipid storage or clearance were altered. Total circulating cholesterol, TG, and free fatty acid levels were much lower in PKCβ−/− mice compared with WT mice (Fig. 4C). Fasting free fatty acid levels were not statistically different, but there was a tendency for elevation of these levels in PKCβ−/− mice (results not shown). Mean rectal temperature (97.8 ± 0.3°C [WT] versus 98.9 ± 0.4°C [PKCβ−/−]; P < 0.01) or skin temperature (95.9 ± 0.4°C [WT] versus 98.1 ± 0.5°C [PKCβ−/−]; P < 0.01) was slightly higher in PKCβ−/− mice relative to those of control mice (Fig. 4D). Increased body temperatures in PKCβ−/− mice compared with WT mice point toward increased thermogenesis in the mutant mice. In short, these results demonstrate that PKCβ deficiency imparts resistance to diet-induced obesity and liver steatosis.

Altered Expression of Genes Involved in Lipolysis, Fatty Acid Synthesis, and Oxidation in HFD-Fed PKCβ−/− Mice.

Having shown that HFD-induced adiposity is ameliorated in mice lacking PKCβ, we next examined changes in the expression profiles of genes involved in lipid uptake, storage, and metabolism. The most striking changes were seen in genes involved in lipogenesis and fatty acid β-oxidation in the liver. The expression levels of acetyl-CoA carboxylase-2, a negative regulator of carnitinepalmitoyltransferase-1 activity and fatty acid oxidation, were significantly reduced in PKCβ−/− mice, indicating an increase in β-oxidation. Reduced hepatic expression levels of genes encoding fatty acid synthase, sterol response element-binding protein (SREBP)-1a, and SREBP-1c point to a decrease in TG biosynthesis (Table 1). Consistent with mRNA levels, western blot analysis revealed reduced amount of mature SREBP-1 in the livers of PKCβ−/− mice compared with WT mice (Fig. 4E).

Table 1. Expression of Various mRNAs in WAT, BAT, and Livers of Mice Fed a High-Fat Diet for 12 weeks
GeneRelative Fold Change
WATBATLiver
  1. The fold change is calculated as the ratio of knockout/control expression and is an average of two experiments.

  2. Abbreviation: ND, not determined.

SREBP-1a0.570.530.61
SREBP-1c0.510.60.4
SREBP-21.71.41.0
C/EBPα1.01.0ND
LRP-10.91.01.0
FAS0.30.530.7
Perilipin A0.20.85ND
ACC-2ND0.90.47
HSL1.5ND1.0
ATGL1.01.0ND
CD361.0NDND
SCD-11.01.01.0
UCP-1ND1.0ND
UCP-21.31.31.0
UCP-30.340.370.5

To begin to understand changes in adipose tissue resulting from PKCβ deficiency, differentially regulated genes were also characterized. We focused on enzymes and proteins that reside at the lipid droplet surface that are thought to play a pivotal role in the lipolysis and/or lipid droplet formation. Hormone-sensitive lipase mRNA was elevated in the adipose tissue of PKCβ−/− mice compared with WT adipose tissue, whereas mRNA levels for adipose TG lipase did not change in PKCβ−/− mice. mRNA for perilipin A, a lipid droplet protein intimately involved in lipolysis that may serve as a scaffold for droplet-associated regulatory proteins, was reduced in PKCβ−/− adipose tissue. In contrast, multiple genes involved in lipid homeostasis (C/EBPα, low-density lipoprotein receptor–related protein-1, and CD36) were not changed in PKCβ−/− mice compared with WT mice (Table 1). We also examined the expression of genes encoding uncoupling proteins (UCPs), because it appears that PKCβ−/− mice expend more energy in thermogenesis than control mice. Expression of UCP-2 in WAT was slightly elevated in PKCβ−/− WAT and BAT, but not in the liver, whereas expression of UCP-3 was significantly reduced in all three tissues examined.

PKCβ−/− Mice Exhibit Increased Insulin Sensitivity.

Diet-induced obesity is frequently associated with insulin resistance, so we next investigated whether depletion of PKCβ would affect insulin sensitivity. Plasma glucose and insulin levels were significantly higher in fasted WT mice compared with those in PKCβ−/− mice after 12 weeks of HFD feeding, indicating resistance to the emergence of insulin resistance (Fig. 5A). Glucose tolerance tests indicated that PKCβ−/− mice on an HFD were more efficient in clearing an intraperitoneally injected bolus of glucose than WT mice on the same diet (Fig. 5B). Protection from diet-induced insulin resistance in PKCβ−/− mice was also confirmed by an insulin tolerance test. Insulin sensitivity, as measured by the degree of reduction in plasma glucose after insulin administration, reflected that PKCβ−/− mice on an HFD were more efficient at insulin-mediated suppression of plasma glucose than WT mice (Fig. 5B). These results demonstrate that the absence of PKCβ clearly hindered the development of HFD-induced insulin resistance in HFD-induced obesity and suggest that supporting mechanisms may be linked to reduced TG contents.

Figure 5.

Increased in vivo insulin sensitivity in PKCβ−/− mice compared with WT mice following 12 weeks of an HFD. (A) Plasma glucose and plasma insulin were measured after 12 weeks on an HFD in WT and PKCβ−/− mice. Data are expressed as the mean ± standard deviation (n = 6). (*P < 0.05). (B) Changes in glucose levels in insulin tolerance tests (ITT) and glucose tolerance tests (GTT). For the insulin tolerance test, mice fasted for approximately 16 hours were injected with insulin (0.8 U/kg body weight), blood samples were obtained at the indicated times, and glucose levels were monitored. For the glucose tolerance test, mice fasted for approximately 16 hours were injected with a bolus of glucose (1.5 mg/kg), and blood samples were obtained at the indicated times and analyzed for glucose levels. Data are expressed as the mean ± standard deviation (n = 6). *P < 0.05; **P < 0.001.

We finally investigated the relationship of adipose PKCβ expression with any of the parameters characteristic for obesity and insulin resistance. Dietary fat may increase PKCβ levels directly through an effect on lipid metabolic machinery or indirectly by changing other metabolic parameters. Dietary studies were performed using another group of WT mice, and plasma insulin and adipose PKCβ expression levels were determined after HFD feeding for varying periods (0, 2, 4, or 8 weeks). As shown in Fig. 6A, the increase in PKCβ expression was observed with HFD in a time-dependent manner, which paralleled an increase in plasma insulin levels. To confirm the association between adipose PKCβ expression and insulin levels, we further investigated the effect of insulin on PKCβ expression in primary adipocytes from C57BL/6J mice. The freshly isolated adipocytes were plated in Kreb-Riger, containing 1% BSA, and after 1 hours cells were switched to media containing 10 nM insulin and harvested after varying intervals. Treatment of these cells with insulin induced PKCβ expression in a time- and dose-dependent manner (Fig. 6B), thus supporting involvement of hyperinsulinemia in HFD-dependent induction of adipose PKCβ expression.

Figure 6.

Plasma insulin and adipose PKCβ expression in WT mice fed an HFD for the indicated periods and PKCβ expression by insulin in primary adipocytes. (A) In order to test the efficacy of an HFD treatments, plasma insulin levels and adipose PKCβ expression were measured in WT mice fed a normal chow diet or an HFD for 0, 2, 4, and 8 weeks. (B) Time-dependent changes in PKCβ expression by insulin in primary adipocytes from WT mice. Freshly isolated primary adipocytes were treated with 10 nM insulin for the indicated times. Results are plotted relative to the control value set at 1. All data are expressed as the mean ± standard deviation (n = 4). *P < 0.05.

Discussion

This study demonstrates nutritional regulation of the PKCβ gene in vivo. In particular, we report prominent up-regulation of PKCβ expression in the fat tissues of two obese animal models, ob/ob and HFD-fed mice, suggesting tissue- and isoform-specific differences in the mechanisms regulating PKC isoforms expression in response to dietary fat. Differential regulation of individual PKC isoforms has earlier been observed under various physiological and pathological conditions.14, 16 An important question is whether the delayed change in PKCβ gene expression is a result of exposure to HFD or the resulting insulin resistance. It is conceivable that diet-induced insulin resistance may contribute to the induction of adipose PKCβ gene expression. As a consequence of increased insulin resistance, insulin levels are elevated in these mice, which in turn can induce PKCβ expression. In support of this idea, we observed an increase in plasma insulin levels in HFD-fed WT mice that paralleled closely with increased PKCβ expression in adipose tissue. Furthermore, hyperinsulinemic ob/ob mice exhibited elevated basal PKCβ expression in WAT. Lastly, induction of adipose PKCβexpression can be reproduced ex vivo by treating adipose tissue organ cultures with insulin, the classic hormone of the fed state37 (Fig. 6). Given that insulin stimulates SREBP-1c expression and activity,38, 39 the mechanism of induction may at least in part include multiple SRE-1 sites present in the PKCβ promoter.40, 41 We therefore propose that increased PKCβ expression observed in HFD-fed mice is secondary to increased caloric consumption and the consequent insulin resistance, rather than to the HFD itself. The nature of the signaling pathway that triggers differential PKCβ expression in a tissue-specific manner remains to be characterized. Adipose-selective PKCβ induction may be related to tissue-specific promoter events, because transgenic mice overexpressing SREBP-1c in the liver42 or adipose tissue43 exhibited different phenotypes, possibly due to tissue-specific action of SREBP-1c resulting in differential gene expression. Additionally, HFD-dependent development of hepatic insulin resistance could prevent insulin-mediated changes in gene expression. Future studies to identify the precise mechanisms underlying this effect will be of interest.

The adipose-selective induction of PKCβ expression, in addition to being a consequence of HFD-induced hyperinsulinemia, may also have direct effects on the development of obese phenotype in WT mice. In accordance with this possibility, we report that PKCβ−/− mice are resistant to HFD-induced obesity, as reflected by lower body weight, smaller visceral fat pads, decreased fat accumulation in the liver, and better insulin sensitivity. The PKCβ−/− phenotype is distinct from lipodystrophic mice, a class of lean mice that have defects in white adipocyte differentiation or function.43–45 Lipodystrophic mice lack normal adipocytes and accumulate fat in nonadipose tissues, resulting in fatty livers, elevated circulating TG levels, and insulin resistance. In contrast, PKCβ−/− mice exhibit decreased lipid storage in adipose tissue but do not exhibit increased circulating TG levels or hepatic steatosis. In fact, reduced accumulation of fat in the liver is characteristic of PKCβ−/− mice and is consistent with reduced expression of lipogenic genes such as FAS, SREBP-1c, and SREBP-1a in the liver. PKCβ−/− mice also differ from other classes of lean mice resulting from alterations in central nervous system–mediated gene targets. For example, leptin transgenic mice,46 or knockout mice in melanin concentrating hormone47 or the muscarinic M3 receptor,48, 49 exhibit increased metabolic rates but rarely exhibit compensatory increase in food intake. Interestingly, PKCβ−/− mice exhibit some similarity to a class of lean mice resulting from a reduction in adipose tissue storage capacity, or by enhanced lipolysis, which can be induced by the disruption of a number of genes.50–53 Reduced energy storage consistently results in increased energy expenditure due to repartitioning of energy substrates up to a point where increased food intake cannot compensate.

Possible scenarios can be envisioned that may account for mechanisms by which PKCβ deficiency imparts resistance to HFD-induced obesity. Increased oxygen consumption and differential thermogenesis may contribute to protection in PKCβ−/− mice.32 Body temperatures of PKCβ−/− mice were slightly higher than WT mice, suggesting that protection from obesity in PKCβ−/− mice most likely involves increased energy expenditure. It is consistent with previous studies that have shown that diet-induced thermogenesis is higher in lean humans compared with obese individuals.53 Potential mechanisms regulating this process may involve reduced hepatic malonyl-CoA levels in PKCβ−/− mice. Recent reports have indicated that reduced malonyl-CoA levels are associated with increased fat oxidation, because reduction of acetyl-CoA carboxylase-2 expression in PKCβ−/− mice would down-regulate mitochondrial malonyl-CoA, thus releasing its inhibition of CPT-1 activity, and thereby stimulating β-oxidation.54, 55 Decreased plasma insulin levels may be responsible for reduced hepatic acetyl-CoA carboxylase-2 expression in PKCβ−/− mice.56 Moreover, altered expression of genes involved in fatty acid synthesis in the liver may further contribute to changes in the PKCβ−/− mice. The lean phenotype could be due to reduced lipogenesis, because we have observed significantly reduced expression of SREBP-1c and its target gene encoding fatty acid synthase. It appears that the combined effect of increased fatty acid oxidation and decreased lipid synthesis in the livers of PKCβ−/− mice may in part account for resistance of the PKCβ−/− mice to acquisition of a fatty liver.

Our results also uncovered an important regulatory role for PKCβ in altering adipose lipid metabolism, including misregulated lipolysis, storage, and lipogenesis. Our analysis indicates elevated adipose hormone-sensitive lipase mRNA in PKCβ−/− mice. Also, PKCβ−/− mice adipose has decreased perilipin A expression thereby promoting increased lipolysis. Furthermore, FAS expression was decreased in PKCβ−/− adipose tissue relative to WT tissue. In addition, UCP-3 expression is decreased in both WAT and BAT of PKCβ−/− mice. In rodents and humans, administration of fatty acids increased muscle UCP-3 expression.57, 58 However, UCP-3 is also regulated by several factors, including thyroid hormone, β3-adrenergic agonists, and leptin, as well as fat feeding in rodents. One or more of these factors may be responsible for the down-regulation of UCP-3 in PKCβ−/− mice. Our results may reconcile studies that have shown increased UCP-3 mRNA in type 2 diabetic patients characterized by higher TG levels.58 Our observation that PKCβ−/− mice exhibit decreased UCP-3 expression and reduced fat mass is consistent with human association studies. We thus favor the interpretation that protection from obesity with the PKCβ deficiency is mechanistically linked to reduced energy storage as a consequence of increased oxidation of energy that would otherwise be stored. It remains to be seen if high levels of PKCβ may be a component of the obesity risk profile.

It is also likely that contributions from other sites of PKCβ action may regulate energy expenditure. In particular, PKCβ is also expressed in the brain (Mehta et al., unpublished results), and it may influence PKCβ-dependent signaling events mediated by either insulin and/or leptin at this site. Although it has been suggested that insulin-mediated signaling in the hypothalamus controls sympathetic outflow and indirectly stimulates energy expenditure, it is not firmly established that the metabolic effects of insulin in the hypothalamus are dependent upon the activity of PKCβ. α recent report has linked PKCβ to β-adrenergic signaling in adipocytes.59 Likewise, occurrence of adaptive changes in lipid metabolism in liver that does not induce this gene in response to an HFD indicates the importance of cross-talk between adipose and liver and has been documented repeatedly.60–63 Adipokines are known to act via endocrine, paracrine, autocrine, and/or juxatacrine modes of action to modulate fat depot size and body fat redistribution and ultimately influence obesity and liver damage. Both leptin and adiponectin have been demonstrated to increase rates of fatty acid oxidation and decrease lipid contents.63, 64 An increase in body fat causes an increase in circulating leptin levels, which will normally decrease the energy intake and increase energy expenditure; yet in WT mice, the ratio of leptin to body weight and fat mass was much higher than that in PKCβ−/− mice. Thus, unlike PKCβ−/− mice, WT mice develop leptin resistance with HFD, mimicking humans with diet-induced obesity. There are at least two potential mechanisms by which PKCβ may influence leptin sensitivity in mice. First, it may positively regulate leptin transcription, and PKCβ deficiency reduces leptin expression. Our results demonstrating that leptin mRNA expression is markedly reduced in PKCβ−/− mice implicates PKCβ-dependent mechanisms in the transcription control of leptin promoter. Modulation of transactivation potential of Sp1 and HIF-1α through phosphorylation by multiple kinases, including PKC and p42/44MAPK, strongly supports such a possibility.65 Alternatively, PKCβ may be necessary for other reactions and processes required for reducing transmission of the leptin signal to the effector molecules. There is significant but indirect evidence to suggest that one or more calcium-dependent PKCs may play a major role in influencing leptin signaling. These two mechanisms may also operate in a synergistic fashion to simultaneously influence leptin expression and signaling. In addition, PKCβ−/− mice showed a slight increase in adiponectin levels, without significantly increasing adiponectin mRNA levels in either WAT or BAT. It is not known if the modest increase in adiponectin in PKCβ−/− mice functionally accounts for increased fatty acid oxidation and decreased hepatic steatosis.

It is interesting to note that in contrast to human subjects and several mouse models of lipodystrophy,43–45 loss of adiposity in PKCβ−/− mice also led to increased insulin sensitivity. Reduced TG content in PKCβ−/− mice skeletal muscle or liver may enhance insulin sensitivity in these tissues.66, 67 Several additional features of the PKCβ−/− phenotype may contribute to increased insulin sensitivity in these mice. In particular, decreased adipocyte size, as we have observed in PKCβ−/− mice, is associated with increased insulin sensitivity. Also, hormonal effects of PKCβ deficiency may alter insulin sensitivity. Altered plasma levels of adipokines are frequently seen in patients with type 2 diabetes.68 Reduced adipose tissue in PKCβ−/− mice is expected to alter plasma adipokines levels, thereby affecting glucose metabolism. In support of this possibility, dramatic reduction of leptin levels were observed in PKCβ−/− mice, and lower leptin levels have been correlated with insulin sensitivity.69 In view of insulin regulating leptin gene expression,70 it is likely that low insulin levels in PKCβ−/− mice account for markedly reduced leptin levels. The increase in plasma adiponectin levels may have additionally contributed to improvements in insulin sensitivity directly or through the enhancement of insulin action.71 What is also interesting is the observation that, despite the significant disparity in fat mass, PKCβ−/− mice displayed slightly higher levels of adiponectin compared with WT mice on an HFD. We suggest that PKCβ deficiency might increase plasma adiponectin levels in the context of a lean phenotype to levels slightly higher than those observed in WT mice, due to posttranslational control of protein secretion and degradation within the secretory pathway.72, 73 It appears that, in the setting of HFD-induced obesity, PKCβ may be a potential intermediary molecule linking obesity to liver damage and insulin resistance.

In conclusion, our study has revealed a role for PKCβ in diet-induced obesity. Our study suggests that a consequence of PKCβ deficiency is an activation of lipid oxidation in addition to reduced fatty acid synthesis and storage. It seems reasonable to propose that PKCβ is required in a signaling pathway that facilitates energy storage in response to an HFD, in part by triggering biological responses designed to paradoxically increase the efficiency of energy storage. This would represent an example of the “thrifty gene” phenotype and represent an advantage during times of food shortage.74 However, in times of feast and a sedentary lifestyle, such as the present, PKCβ appears to provide a survival disadvantage, causing an epidemic of hypertrophic obesity. It is possible that up-regulation of PKCβ expression and desensitization of insulin signaling in accumulated fat may serve as one of the mechanisms for maintaining obesity. Another intriguing finding is that few insulin signaling mediators have been reported to be diet-regulated at the transcriptional level in adipose tissue.75 Our study provides evidence that an insulin-signaling kinase (PKCβ) is physiologically regulated at the transcriptional level in adipose tissue by dietary fat. Our data provide support for the hypothesis that adipose PKCβ is controlled specifically by factors responding to the consumption of dietary fat and that the expression of PKCβ is linked to the development of obesity. Future studies will determine whether induction of adipose PKCβ expression constitutes an early defect in the pathogenesis of obesity. It is anticipated that suppression of PKCβ expression or activity could be therapeutically effective for the management and prevention of obesity and related disorders. 7

Figure 7.

Schematic diagram of the hypothetical sequence of events whereby an HFD-induced hyperinsulinemia stimulates expression of SREBP-1c, which in turn increases PKCβ expression and promotes TG storage and hepatic steatosis.

Ancillary